I like your comment 'By my estimation'. Acrux is always hiding behind confidentiality and as a result they never seem to be able to say what they are going to do and when - how convenient - they never have to answer to holders for failing to hit the deadline.
They seemed to imply in the annual report that Eficonezal is next given it was the 'furthest along' and they said they were releasing one product in 1st Half of this year.
But In the end, they have kept it all under wraps as usual. No way to know for sure.,
ACR Price at posting:
6.8¢ Sentiment: Sell Disclosure: Held
